Niagen Bioscience, Inc. current report, 30 June 2019

Business Context and Reporting Period

This Form 8-K is filed by ChromaDex Corporation (not Niagen Bioscience, Inc.) for the reporting period ending June 30, 2019. The filing reports on amendments to a material definitive agreement regarding a convertible note financing.

Key Financial Metrics

The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. The only specific financial metric disclosed is related to the debt instrument:

  • Convertible Notes Principal: $10.0 million (issued May 17, 2019).
  • Debt Maturity Date: Extended from July 1, 2019, to August 15, 2019.

Material Changes

On June 30, 2019, the Company and the Purchasers (Winsave Resources Limited and Pioneer Step Holdings Limited) executed an Omnibus Amendment to the Note Purchase Agreement. The material changes include:

  • Removal of Issuance Restriction: The restriction on the Company issuing Common Stock during the "Restricted Period" was removed.
  • Extension of Maturity: The maturity date of the $10.0 million convertible promissory notes was extended by 45 days, from July 1, 2019, to August 15, 2019.

Guidance, Outlook, and Risks

The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the context of the debt amendment. The document notes that the description of the Omnibus Amendment is qualified by reference to the full text of the agreement attached as Exhibit 99.1.

Investor Verification Checklist

  • Verify the full terms of the Omnibus Amendment in Exhibit 99.1 to understand any additional covenants or conditions not summarized in the 8-K.
  • Confirm the Company's ability to repay or convert the $10.0 million note by the new maturity date of August 15, 2019.
  • Review subsequent filings to determine if the Company issued Common Stock following the removal of the issuance restriction.
  • Clarify the relationship between the registrant (ChromaDex Corporation) and the entity name provided in the request metadata (Niagen Bioscience, Inc.), as the filing explicitly identifies ChromaDex.